Big Ag just became humongous.

On 4 July, Bayer AG, the German multinational pharma company, bought the world’s most controversial agriculture company, Monsanto, in a $66-billion deal that gave Bayer control over a whopping 30% of the global seed market and a quarter of the pesticide market.

The merger, two years in the making, is part of a wave. US’ DowDupont and China’s ChemChina-Syngenta were formed through a merger in 2017. With Bayer-Monsanto (Bayer will later drop the Monsanto tag), 61% of the global seed and pesticide market will be in the hands of just three players. In 2016, there were six major rivals.

Indian seed companies, “small ag”, were alert, of course. So was the Competition Commission of India (CCI), the anti-trust regulator that monitors competition. The repercussions could be immense as agriculture drives India’s economy. The sector is closely monitored by outspoken activists like Vandana Shiva and Greenpeace, for whom corporate agriculture in general and Monsanto, in particular, represent corporate evil. They claimed that the merger could eliminate competition in certain markets and drive up seed and pesticide prices, making Indian farmers beholden to foreign corporate interests. In 2015, Monsanto, Bayer, or both, were dominant players in the Indian market for branded hybrid seeds of cotton, rice and at least 10 vegetable seeds. Bayer holds 40% of the hybrid rice market in India, for example.

“These are two very well positioned companies in India,” says David Spielman, senior research fellow at the International Food Policy Research Institute (IFPRI) in Washington, DC. “India and most other countries need to constantly be monitoring the effects of merger and industry consolidation on competitiveness and prices that farmers pay for these inputs.”

In May, CCI approved the merger with careful conditions. Bayer needs to sell a part of its herbicide and seeds business to an independent third party, and Monsanto needs to divest its 26% stake in Maharashtra Hybrid Seeds (Mahyco), a major Indian seed company. Bayer is planning to divest the businesses to Germany’s chemical company BASF, contingent on CCI approval. CCI has also asked Bayer to license on fair terms its digital platform that analyses agronomic data to recommend to farmers how best to use fertilizer, seeds and herbicides. It has asked Bayer to grant the government seven years of free access to agro-climatic data.

With CCI’s conditions in place, Indian seed and chemical companies are not very worried, according to interviews with industry executives. But perhaps they should be. Agriculture is undergoing rapid transformation to digital and Big Ag is helming that trend. In official-speak, CCI laid out its assessment thus: “Post combination, the Combined Entity’s [Bayer-Monsanto’s] transformation into a one-stop-shop platform, providing packaged solutions to the farmers in the seed and traits value chain and the agrochemical supply chain through their digital applications would lead to enhancement of its market power vis-à-vis its competitors who may be unable to offer similar integrated services to the farmers… The Combined Entity would enable more data capture, the ability to spread development costs and allocate more resources to simply out-spend smaller competitors.

AUTHOR

Gayathri Vaidyanathan

Gayathri writes on health, environment and science. She has reported and produced stories for the Washington Post, Discover, Nature, and the New York Times, amongst other publications. In her last assignment, she was the lead science writer for E&E News in Washington, D.C. E&E News is a news organisation focused on energy and the environment. Over the past decade, Gayathri has travelled across North America, Africa and Asia on long-form reporting projects. She has a master’s in journalism from Columbia University and a bachelor's in biochemistry from McMaster University in Ontario. At The Ken, Gayathri will write on healthcare, the pharmaceutical business and the environment. Based in Bengaluru, you can reach her at gayathri at the rate the-ken.com

View Full Profile

Available exclusively to subscribers of The Ken India

This story is a part of The Ken India edition. Subscribe. Questions?

MOST POPULAR

Annual Subscription

12-month access to 200+ stories, archive of 800+ stories from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 2,750

Subscribe
 

Quarterly Subscription

3-month access to 60+ new stories with 3-months worth of archives from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 1,750

Subscribe
 

Single Story

Instant access to this story for a year along with comment privileges.

Rs. 500

Subscribe
MOST POPULAR

Annual Subscription

12-month access to 150+ stories from Southeast Asia.

$ 120

Subscribe
 

Quarterly Subscription

3-month access to 35+ stories from Southeast Asia.

$ 50

Subscribe
 

Single Story

Instant access to this story for a year along with comment privileges.

$ 20

Subscribe

Questions?

What is The Ken?

The Ken is a subscription-only business journalism website and app that provides coverage across two editions - India and Southeast Asia.

What kind of stories do you write?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics.

We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

What do I get if I subscribe?

For subscribers of the India edition, we publish a new story every weekday, a premium daily newsletter, Beyond The First Order and a weekly newsletter - The Nutgraf.

For subscribers of the Southeast Asia edition, we publish a new story three days a week and a weekly newsletter, Strait Up.

The annual subscription will get you complete, exclusive access to our archive of previously published stories for your edition, along with access to our subscriber-only mobile apps, our premium comment sections, our newsletter archives and several other gifts and benefits.

Do I need to pay separately for your premium newsletters?

Nope. Paid, premium subscribers of The Ken get our newsletters delivered for free.

Does a subscription to the India edition grant me access to Southeast Asia stories? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

Do you offer an all-access joint subscription for both editions?

Not yet. If you’d like to access both editions, you’ll have to purchase two subscriptions separately - one for India and the other for Southeast Asia.

Do you offer any discounts?

No. We have a zero discounts policy.

Is there a free trial I can opt for?

We don’t offer any trials, but you can sign up for a free account which will give you access to the weekly free story, our archive of free stories and summaries of the paid stories. You can stay on the free account as long as you’d like.

Do you offer refunds?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Please write to us at [email protected] detailing the error or queries.